menu search

GILD / Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, from November 10-14, 2023. Key findings from more than 80 presentations will include a late-breaker oral presentation of primary endpoint results from the Phase 2b MYR204 study evaluating Hepcludex® (bulevirtide), an investigational therapy in the U.S. and outside of the Eur. Read More
Posted: Nov 3 2023, 11:00
Author Name: Business Wire
Views: 072484

GILD News  

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

By Business Wire
November 3, 2023

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the America more_horizontal

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

By Zacks Investment Research
October 30, 2023

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day. more_horizontal

Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?

By Zacks Investment Research
October 30, 2023

Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 resul more_horizontal

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

By Zacks Investment Research
October 24, 2023

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close. more_horizontal

7 Healthcare Stocks to invest in for a Healthy Future

By InvestorPlace
October 20, 2023

7 Healthcare Stocks to invest in for a Healthy Future

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant develop more_horizontal

GILD or VRTX: Which Is the Better Value Stock Right Now?

By Zacks Investment Research
October 19, 2023

GILD or VRTX: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). Bu more_horizontal

Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs

By Market Watch
October 17, 2023

Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs

Gilead Sciences Inc. GILD, +2.00% announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB, +2.11% to develop antiviral therapies, with more_horizontal

Gilead Sciences Stock Is Cheap, With Broad Pipeline

By Seeking Alpha
October 15, 2023

Gilead Sciences Stock Is Cheap, With Broad Pipeline

Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis more_horizontal


Search within

Pages Search Results: